Cite
HARVARD Citation
Ngamphaiboon, N. et al. (n.d.). 286OPhase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis. Annals of oncology. p. . [Online].